Source comparison
Tesamorelin + Ipamorelin: Peptide Blend Comparison
Tesamorelin GHRH analog. Binds GHRH receptors on pituitary somatotrophs, stimulating GH synthesis and release 1–2mg once daily 30–45 min before first meal Primes pituitary for Ipamorelin's ghrelin-mimetic signal; direct visceral adipocyte lipolysis independent
This comparison does not assign a generated winner or score.
- Tesamorelin
- GHRH analog. Binds GHRH receptors on pituitary somatotrophs, stimulating GH synthesis and release
- 1–2mg once daily
- 30–45 min before first meal
- Primes pituitary for Ipamorelin's ghrelin-mimetic signal; direct visceral adipocyte lipolysis independent of GH pulse
- Required anchor compound for visceral fat reduction. Ipamorelin alone does not replicate this effect
- Ipamorelin
- Ghrelin receptor agonist. Triggers endogenous GH pulse without cortisol or prolactin elevation
- 200–300mcg 2–3× daily
- Minimum 2hr post-meal, 90min pre-meal
- Amplifies Tesamorelin-primed GH pulse 3–5× baseline; restores youthful pulsatile secretion pattern
- Dose above 300mcg per injection shows no additional GH response. Higher doses waste compound
- CJC-1295 (DAC)
- GHRH analog with extended half-life (6–8 days)
- 1–2mg weekly
- Any time, non-fasting
- Alternative to Tesamorelin for researchers preferring weekly dosing vs daily administration
- Lacks Tesamorelin's direct visceral adipocyte targeting. General GH elevation only